FOLLOWUS
- Share with wechat friends or circle of friends
Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis
- Affiliations：
Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Author bio：
* 通讯作者：李学旺,Email：xuewanglee@126.com
- Funds：Fund supported by the Key Projects of the National Science and Technology Pillar Program during the Twelfth Five-year Plan Period(2011BAI10B03)
DOI：10.24920/21803
中图分类号：收稿日期：2017-07-31，
网络出版日期：2018-02-13，
纸质出版日期：2018-04-01
- Accepted：
Scan QR Code
邹佩美, 李航, 蔡建芳, 等. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis[J]. Chinese Medicine Science Journal, 2018,33(1):9-19.
Zou Peimei, Li Hang, Cai Jianfang, et al. 利妥昔单抗在特发性膜性肾病中的治疗[J]. Chinese medicine science journal, 2018, 33(1): 9-19.
邹佩美, 李航, 蔡建芳, 等. Therapy of Rituximab in Idiopathic Membranous Nephropathy with Nephrotic Syndrome: A Systematic Review and Meta-analysis[J]. Chinese Medicine Science Journal, 2018,33(1):9-19. DOI： 10.24920/21803.
Zou Peimei, Li Hang, Cai Jianfang, et al. 利妥昔单抗在特发性膜性肾病中的治疗[J]. Chinese medicine science journal, 2018, 33(1): 9-19. DOI： 10.24920/21803.
摘要
Abstract
关键词
Keywords
references
Schieppati A , Mosconi L , Perna A , et al . Prognosis of untreated patients with idiopathic membranous nephropathy . N Engl J Med , 1993 ; 329 ( 2 ): 85 - 9 . doi: 10.1056/NEJM199307083290203 https://doi.org/10.1056/NEJM199307083290203 . DOI: 10.1007/BF00866338 http://doi.org/10.1007/BF00866338 http://www.nejm.org/doi/abs/10.1056/NEJM199307083290203 http://www.nejm.org/doi/abs/10.1056/NEJM199307083290203
Chen Y , Schieppati A , Chen X , et al . Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome . Cochrane Database Syst Rev 2014 ; (10):CD004293. doi: 10.1002/14651858.CD004293.pub3 https://doi.org/10.1002/14651858.CD004293.pub3 .
Beck LH , Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy . N Engl J Med , 2009 ; 361 ( 1 ): 11 - 21 . doi: 10.1056/NEJMoa0810457 https://doi.org/10.1056/NEJMoa0810457 . DOI: 10.1056/NEJMoa0810457 http://doi.org/10.1056/NEJMoa0810457 http://www.nejm.org/doi/abs/10.1056/NEJMoa0810457 http://www.nejm.org/doi/abs/10.1056/NEJMoa0810457
Cattran D . Management of membranous nephropathy: when and what for treatment . J Am Soc Nephrol , 2005 ; 16 ( 5 ): 1188 - 94 . doi: 10.1681/ASN.2005010028 https://doi.org/10.1681/ASN.2005010028 . DOI: 10.1681/ASN.2005010028 http://doi.org/10.1681/ASN.2005010028 http://www.jasn.org/cgi/doi/10.1681/ASN.2005010028 http://www.jasn.org/cgi/doi/10.1681/ASN.2005010028
Cattran DC . Idiopathic membranous glomerulonephritis . Kidney Int , 2001 ; 59 ( 5 ): 1983 - 94 . doi: 10.1046/j.1523-1755.2001.0590051983.x https://doi.org/10.1046/j.1523-1755.2001.0590051983.x . DOI: 10.1046/j.1523-1755.2001.0590051983.x http://doi.org/10.1046/j.1523-1755.2001.0590051983.x http://linkinghub.elsevier.com/retrieve/pii/S0085253815476926 http://linkinghub.elsevier.com/retrieve/pii/S0085253815476926
Sinha A , Bagga A . Rituximab therapy in nephrotic syndrome: implications for patients’ management . Nat Rev Nephrol , 2013 ; 9 ( 3 ): 154 - 69 . doi: 10.1038/nrneph.2012.289 https://doi.org/10.1038/nrneph.2012.289 . DOI: 10.1038/nrneph.2012.289 http://doi.org/10.1038/nrneph.2012.289 http://www.nature.com/nrneph/journal/v9/n3/abs/nrneph.2012.289.html http://www.nature.com/nrneph/journal/v9/n3/abs/nrneph.2012.289.html
Remuzzi G , Chiurchiu C , Abbate M , et al . Rituximab for idiopathic membranous nephropathy . Lancet , 2002 ; 360 ( 9337 ): 923 - 4 . doi: 10.1016/S0140-6736(02)11042-7 https://doi.org/10.1016/S0140-6736(02)11042-7 . DOI: 10.1016/S0140-6736(02)11042-7 http://doi.org/10.1016/S0140-6736(02)11042-7 http://linkinghub.elsevier.com/retrieve/pii/S0140673602110427 http://linkinghub.elsevier.com/retrieve/pii/S0140673602110427
Moher D , Liberati A , Tetzlaff J , et al . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement . Int J Surg , 2010 ; 8 ( 5 ): 336 - 41 . doi: 10.1016/j.ijsu.2010.02.007 https://doi.org/10.1016/j.ijsu.2010.02.007 . DOI: 10.1016/j.ijsu.2010.02.007 http://doi.org/10.1016/j.ijsu.2010.02.007 http://linkinghub.elsevier.com/retrieve/pii/S1743919110000403 http://linkinghub.elsevier.com/retrieve/pii/S1743919110000403
Fervenza FC , Canetta PA , Barbour SJ , et al . A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR) . Nephron , 2015 ; 130 ( 3 ): 159 - 68 . doi: 10.1159/000430849 https://doi.org/10.1159/000430849 . DOI: 10.1159/000430849 http://doi.org/10.1159/000430849 https://www.karger.com/Article/FullText/430849 https://www.karger.com/Article/FullText/430849
Rojas-Rivera J , Fernandez-Juarez G , Ortiz A , et al . A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study . Clin Kidney J , 2015 ; 8 ( 5 ): 503 - 10 . doi: 10.1093/ckj/sfv075 https://doi.org/10.1093/ckj/sfv075 . DOI: 10.1093/ckj/sfv075 http://doi.org/10.1093/ckj/sfv075 https://academic.oup.com/ckj/article-lookup/doi/10.1093/ckj/sfv075 https://academic.oup.com/ckj/article-lookup/doi/10.1093/ckj/sfv075
Beck LH Jr ., Fervenza FC , Beck DM , et al . Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy . J Am Soc Nephrol , 2011 ; 22 ( 8 ): 1543 - 50 . doi: 10.1681/ASN.2010111125 https://doi.org/10.1681/ASN.2010111125 . DOI: 10.1681/ASN.2010111125 http://doi.org/10.1681/ASN.2010111125 http://www.jasn.org/cgi/doi/10.1681/ASN.2010111125 http://www.jasn.org/cgi/doi/10.1681/ASN.2010111125
Irazabal MV , Eirin A , Lieske J , et al . Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study . Nephrol Dial Transplant , 2013 ; 28 ( 1 ): 137 - 46 . doi: 10.1093/ndt/gfs379 https://doi.org/10.1093/ndt/gfs379 . DOI: 10.1093/ndt/gfs379 http://doi.org/10.1093/ndt/gfs379 https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs379 https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs379
Segarra A , Praga M , Ramos N , et al . Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients . Clin J Am Soc Nephrol , 2009 ; 4 ( 6 ): 1083 - 8 . doi: 10.2215/CJN.06041108 https://doi.org/10.2215/CJN.06041108 . DOI: 10.2215/CJN.06041108 http://doi.org/10.2215/CJN.06041108 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.06041108 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.06041108
Dahan K , Debiec H , Plaisier E , et al . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up . J Am Soc Nephrol , 2017 ; 28 ( 1 ): 348 - 58 . doi: 10.1681/ASN.2016040449 https://doi.org/10.1681/ASN.2016040449 . DOI: 10.1681/ASN.2016040449 http://doi.org/10.1681/ASN.2016040449 http://www.jasn.org/lookup/doi/10.1681/ASN.2016040449 http://www.jasn.org/lookup/doi/10.1681/ASN.2016040449
Cravedi P , Ruggenenti P , Sghirlanzoni MC , et al . Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy . Clin J Am Soc Nephrol , 2007 ; 2 ( 5 ): 932 - 7 . doi: 10.2215/CJN.01180307 https://doi.org/10.2215/CJN.01180307 . DOI: 10.2215/CJN.01180307 http://doi.org/10.2215/CJN.01180307 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01180307 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01180307
Cravedi P , Sghirlanzoni MC , Marasa M , et al . Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study . Am J Nephrol , 2011 ; 33 ( 5 ): 461 - 8 . doi: 10.1159/000327611 https://doi.org/10.1159/000327611 . DOI: 10.1159/000327611 http://doi.org/10.1159/000327611 https://www.karger.com/Article/FullText/327611 https://www.karger.com/Article/FullText/327611
Fervenza FC , Abraham RS , Erickson SB , et al . Rituximab therapy in idiopathic membranous nephropathy: a 2-year study . Clin J Am Soc Nephrol , 2010 ; 5 ( 12 ): 2188 - 98 . doi: 10.2215/CJN.05080610 https://doi.org/10.2215/CJN.05080610 . DOI: 10.2215/CJN.05080610 http://doi.org/10.2215/CJN.05080610 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.05080610 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.05080610
Fervenza FC , Cosio FG , Erickson SB , et al . Rituximab treatment of idiopathic membranous nephropathy . Kidney Int , 2008 ; 73 ( 1 ): 117 - 25 . doi: 10.1038/sj.ki.5002628 https://doi.org/10.1038/sj.ki.5002628 . DOI: 10.1038/sj.ki.5002628 http://doi.org/10.1038/sj.ki.5002628 http://linkinghub.elsevier.com/retrieve/pii/S0085253815528305 http://linkinghub.elsevier.com/retrieve/pii/S0085253815528305
Moroni G , Depetri F , Del Vecchio L , et al . Low-dose rituximab is poorly effective in patients with primary membranous nephropathy . Nephrol Dial Transplant , 2017 ; 32 ( 10 ): 1691 - 6 . doi: 10.1093/ndt/gfw251 https://doi.org/10.1093/ndt/gfw251 . DOI: 10.1093/ndt/gfw251 http://doi.org/10.1093/ndt/gfw251 http://europepmc.org/abstract/MED/27387472 http://europepmc.org/abstract/MED/27387472
Ruggenenti P . Rituximab in idiopathic membranous nephropathy: a one-year prospective study . J Am Soci Nephrol , 2003 ; 14 ( 7 ): 1851 - 7 . doi: 10.1097/01.ASN.0000071511.35221.B3 https://doi.org/10.1097/01.ASN.0000071511.35221.B3 . DOI: 10.1097/01.ASN.0000071511.35221.B3 http://doi.org/10.1097/01.ASN.0000071511.35221.B3 http://www.jasn.org/cgi/doi/10.1097/01.ASN.0000071511.35221.B3 http://www.jasn.org/cgi/doi/10.1097/01.ASN.0000071511.35221.B3
Ruggenenti P , Chiurchiu C , Abbate M , et al . Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol , 2006 ; 1 ( 4 ): 738 - 48 . doi: 10.2215/CJN.01080905 https://doi.org/10.2215/CJN.01080905 . DOI: 10.2215/CJN.01080905 http://doi.org/10.2215/CJN.01080905 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01080905 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01080905
Troyanov S , Wall CA , Miller JA , et al . Idiopathic membranous nephropathy: definition and relevance of a partial remission . Kidney Int , 2004 ; 66 ( 3 ): 1199 - 205 . doi: 10.1111/j.1523-1755.2004.00873.x https://doi.org/10.1111/j.1523-1755.2004.00873.x . DOI: 10.1111/j.1523-1755.2004.00873.x http://doi.org/10.1111/j.1523-1755.2004.00873.x http://linkinghub.elsevier.com/retrieve/pii/S0085253815501749 http://linkinghub.elsevier.com/retrieve/pii/S0085253815501749
Polanco N , Gutierrez E , Covarsi A , et al . Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy . J Am Soc Nephrol , 2010 ; 21 ( 4 ): 697 - 704 . doi: 10.1681/ASN.2009080861 https://doi.org/10.1681/ASN.2009080861 . DOI: 10.1681/ASN.2009080861 http://doi.org/10.1681/ASN.2009080861 http://www.jasn.org/cgi/doi/10.1681/ASN.2009080861 http://www.jasn.org/cgi/doi/10.1681/ASN.2009080861
Looney RJ , Anolik JH , Campbell D , et al . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab . Arthritis Rheum , 2004 ; 50 ( 8 ): 2580 - 9 . doi: 10.1002/art.20430 https://doi.org/10.1002/art.20430 . DOI: 10.1002/(ISSN)1529-0131 http://doi.org/10.1002/(ISSN)1529-0131 http://doi.wiley.com/10.1002/%28ISSN%291529-0131 http://doi.wiley.com/10.1002/%28ISSN%291529-0131
Zucchelli P , Ponticelli C , Cagnoli L , et al . Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy . Am J Nephrol , 1988 ; 8 ( 1 ): 15 - 20 . DOI: 10.1159/000167547 http://doi.org/10.1159/000167547 https://www.karger.com/Article/FullText/167547 https://www.karger.com/Article/FullText/167547
Ruggenenti P , Debiec H , Ruggiero B , et al . Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy . J Am Soc Nephrol , 2015 ; 26 ( 10 ): 2545 - 58 . doi: 10.1681/ASN.2014070640 https://doi.org/10.1681/ASN.2014070640 . DOI: 10.1681/ASN.2014070640 http://doi.org/10.1681/ASN.2014070640 http://www.jasn.org/cgi/doi/10.1681/ASN.2014070640 http://www.jasn.org/cgi/doi/10.1681/ASN.2014070640
Ordoñez JD , Hiatt RA , Killebrew EJ , et al . The increased risk of coronary heart disease associated with nephrotic syndrome . Kidney International , 1993 ; 44 ( 3 ): 638 - 42 . DOI: 10.1038/ki.1993.292 http://doi.org/10.1038/ki.1993.292 http://linkinghub.elsevier.com/retrieve/pii/S0085253815581738 http://linkinghub.elsevier.com/retrieve/pii/S0085253815581738
Lee T , Derebail VK , Kshirsagar AV , et al . Patients with primary membranous nephropathy are at high risk of cardiovascular events . Kidney Int , 2016 ; 89 ( 5 ): 1111 - 8 . doi: 10.1016/j.kint.2015.12.041 https://doi.org/10.1016/j.kint.2015.12.041 . DOI: 10.1016/j.kint.2015.12.041 http://doi.org/10.1016/j.kint.2015.12.041 http://linkinghub.elsevier.com/retrieve/pii/S0085253816002751 http://linkinghub.elsevier.com/retrieve/pii/S0085253816002751
Lefaucheur C , Stengel B , Nochy D , et al . Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association . Kidney Int , 2006 ; 70 ( 8 ): 1510 - 7 . doi: 10.1038/sj.ki.5001790 https://doi.org/10.1038/sj.ki.5001790 . DOI: 10.1038/sj.ki.5001790 http://doi.org/10.1038/sj.ki.5001790 http://linkinghub.elsevier.com/retrieve/pii/S0085253815521674 http://linkinghub.elsevier.com/retrieve/pii/S0085253815521674
Ponticelli C , Glassock RJ . Glomerular diseases: membranous nephropathy—a modern view . Clin J Am Soc Nephrol , 2014 ; 9 ( 3 ): 609 - 16 . doi: 10.2215/CJN.04160413 https://doi.org/10.2215/CJN.04160413 . DOI: 10.2215/CJN.04160413 http://doi.org/10.2215/CJN.04160413 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.04160413 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.04160413
关联资源
相关文章
相关作者
相关机构
- © 2024 中国医学科学院 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies